Optegra
Established: 2007
Country: Poland
Investors: MidEuropa
Optegra is a leading pan‑European ophthalmology platform providing high‑quality eye care services across Poland, Czechia, Slovakia, the United Kingdom and the Netherlands. During MidEuropa’s ownership, Optegra transformed from a regional operator into a digitally enabled European healthcare champion.
The value creation strategy focused on clinical leadership, patient outcomes and operational excellence, supported by targeted digital innovation and disciplined expansion. This was delivered through standardised patient pathways, investments in advanced surgical equipment, and digital transformation initiatives - including becoming fully paperless and deploying an AI‑powered virtual assistant for pre- and post‑operative patient assessments - improving efficiency as well as the accessibility and quality of care across the network.
By 2025, Optegra had established market‑leading positions in multiple countries, delivering consistent outcomes for patients while building a scalable and resilient healthcare platform.
Peter Byloos
CEO - Optegra
"Partnering with MidEuropa was pivotal in building Optegra into a leading, digitally led pan-European ophthalmology platform. With MidEuropa's backing, we accelerated growth responsibly, empowered our clinical teams with digital tools, and strengthened the capabilities that will benefit our patients and people for years to come."
>170,000
Annual procedures
#1
Player in three Central European markets and #2 in the UK
>2x EBITDA
Growth achieved during ~2 year ownership period
Key achievements
Built a leading pan‑European ophthalmology platform operating across five countries
Achieved #1 market position in three Central European markets and #2 position in the UK
Standardised patient pathways and clinical processes across geographies
Implemented digital solutions, including AI‑enabled patient triage and paperless pathways in the UK
Delivered over 5% percentage‑point uplift in EBITDA margins through operational excellence
Funding history
Backed by MidEuropa through a focused value creation plan centred on clinical quality and scalability
Growth delivered via disciplined M&A and strong organic expansion
Completed eight add‑on acquisitions and entered two new markets (Slovakia and the Netherlands)
Successfully exited via strategic sale to EssilorLuxottica in 2025
Employment impact
Expanded clinical and operational teams across five European markets
Strengthened working practices and employee experience through digital tools
UK operations recognised as one of the Sunday Times’ Best Places to Work in 2025
Investors
